Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25167085 | 0.92 | LMNA (0.47) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL23411388 | 0.87 | SMN1; SMN2 (0.47) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL23410684 | 0.80 | MPO (0.42) | THRBPOLBSMN1; SMN2 | |
| SCHEMBL29967127 | 0.79 | SMN1; SMN2 (0.47) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL23411303 | 0.79 | SMN1; SMN2 (0.47) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL25174780 | 0.78 | LMNA (0.55) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL23411024 | 0.78 | LMNA (0.55) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL25175362 | 0.77 | LMNA (0.47) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL25167081 | 0.75 | LMNA (0.52) | LMNATHRBTP53POLBMAPT | |
| SCHEMBL29891532 | 0.74 | TSHR (0.37) | LMNATHRBTP53POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | LMNA 1953/4885THRB 3233/4885TP53 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.